October 1, 2026 · Gut · DOI: 10.1136/gutjnl-2026-339167

Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: the INTERCEPT programme experience

Listen to this summary

The authors of this study aimed to evaluate the prognostic role of circulating tumor DNA (ctDNA) in detecting minimal residual disease (MRD) in colorectal cancer patients and to assess the lead time for recurrence detection through longitudinal MRD testing. Their findings indicate that ctDNA testing is valuable for risk stratification, revealing a higher recurrence rate in MRD-positive patients and improved sensitivity for recurrence detection with multitimepoint testing. The study highlights the need for further interventional research to establish the clinical utility and optimal implementation of ctDNA testing in practice.

Giulia Maddalena, Kathryn Aziz, Ryan Sun, Timothy E Newhook, Kristin Alfaro, Andrew Bowling, Dylan N Gil, Ramy S Behman, Mahmoud Yousef, Y Nancy You, Tsuyoshi Konishi, Alisha Bent, Ryan Huey, Bryan Kee, Guglielmo Vetere, Emerik Osterlund, Kaysia Ludford, Victoria Serpas, Madhulika Eluri, Jason Willis, John Paul Shen, Maria P Morelli, Emily Kopetz, Sara Lonardi, Christine Parseghian, Kanwal Raghav, Michael Overman, Gayathri Anandappa, Robert A Wolff, James Yao, George J Chang, Van K Morris, Jean-Necolas Vauthey, Arvind Dasari, Scott Kopetz

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play